HBI-002 to Treat Ulcerative Colitis

项目总结 迫切需要开发新的方法来治疗溃疡病患者 结肠炎(UC)，据估计在美国大约有100万成年人受到影响，导致 发病率、癌症风险增加和死亡率。在多项临床前研究中，我们和其他人已经定义了 小剂量外源性一氧化碳(CO)对UC的治疗潜力 消炎、促进组织修复、限制病原菌感染。 到目前为止，吸入的CO气体(ICO)和与载体分子(球茎)结合的CO一直是 在大多数动物和所有临床研究中都有选择。然而，ICO和球茎预计不会 是药物上可接受和可行的慢性治疗选择，因为ICO存在疏忽的风险 由于存在压缩的一氧化碳钢瓶而暴露，以及难以控制剂量和 球茎、载体分子毒理学、稳定性和CO释放特性已被证明是一种 发展的实质性障碍。拟议项目的目标是研究一种新型口腔药物HBI-002 或经直肠给药的一氧化碳药物产品，旨在使慢性一氧化碳在UC中使用。 CO的安全性和耐受性已在五项成功的1期临床研究中得到证实 通过定义明确的临床前数据集，导致FDA批准进行人体试验。HBI-002包括 口服配方，含有准确数量的CO，不与载体分子(即不是球茎)结合 并能有效地从胃肠道吸收。临床前体内药代动力学和 药效学研究证明了概念验证的可行性、耐受性和生物利用度。下一个 开发的一步是证明HBI-002在临床相关的UC AS动物模型中是有效的 已经展示了与其他形式的CO，并更好地了解潜在的作用机制(S)。基座 根据IBD中CO的大量文献，我们将在该项目中检验的中心假设是：HBI-002 将调节免疫反应，以调节炎症，提高存活率，并促进愈合 UC小鼠模型。

PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from Ulcerative Colitis (UC), which is estimated to impact approximately one million adults in the United States, leading to morbidity, heightened risk of cancer, and mortality. In multiple preclinical studies, we and others have defined the therapeutic potential of low-dose exogenous carbon monoxide (CO) in UC, including in simultaneously reducing inflammation, promoting tissue repair, and limiting pathogenic bacterial infection. To date, inhaled CO gas (iCO) and CO bound to carrier molecules (CORMs) have been the modalities of choice in the majority of animal and in all the clinical studies. However, iCO and CORMS are not expected to be pharmaceutically acceptable and viable chronic therapeutic options due to, with iCO, the risk of inadvertent exposure from the presence of compressed CO cylinders as well as difficulties in controlling dosing and, with CORMs, carrier molecule toxicology, stability, and CO release characteristics that have proven to be a substantial barrier to development. The objective of the proposed project is to investigate HBI-002, a novel oral or rectally administered CO drug product that was developed to enable the chronic use of CO in UC. The safety and tolerability of CO has been demonstrated in five successful Phase 1 clinical studies supported by well-defined preclinical data sets that led to approval by the FDA for human testing. HBI-002 comprises an oral formulation containing precise amounts of CO that are not bound to a carrier molecule (i.e. not a CORM) and efficiently absorbed from the gastrointestinal tract. Preclinical in vivo pharmacokinetic and pharmacodynamic studies demonstrated proof-of-concept feasibility, tolerability, and bioavailability. The next step in development is to demonstrate that HBI-002 is effective in clinically relevant animal models of UC as has been shown with other forms of CO and to better understand the potential mechanism(s) of action. Based upon the substantial literature of CO in IBD, our central hypothesis that will be tested in this project is: HBI-002 will modulate the immune response to regulate inflammation, improve survival, and promote healing in UC mouse models.